Meeting date 16 February 2022
CNAV updated its recommendations on the use of booster doses in adolescents and at-risk groups:
Approved vaccination with third dose of Pfizer mRNA SARS-coV2 vaccine to adolescents aged 12 to 17 years.
Immunocompromised persons who have received CoronaVac + CoronaVac + Pfizer_BioNtech + Pfizer-BioNtech: Fifth dose of Pfizer mRNA platform vaccine to 6 months after last dose
Immunocompromised persons who have received Pfizer-BioNtech + Pfizer-BioNtech + Pfizer-BioNtech: Fourth dose of Pfizer mRNA platform vaccine starting at age 6 months from last dose
Fourth dose of Pfizer_BioNtech mRNA platform vaccine to people aged 70 and more years from 6 months of the third dose
Fourth dose of Pfizer-BioNtech mRNA platform vaccine for people aged 50 years and more who reside in long-stay establishments such as ELEPEM and others from 6 months after the third dose
Fourth dose of Pfizer_BioNtech mRNA platform vaccine to people over 50 years and over who present previously defined comorbidities throughout the Plan National Vaccination or Down Syndrome from 6 months after the third dose
Continue to strongly recommend Universal vaccination of all groups included in the vaccination plan with the primary schedule of two doses and with the third dose to those who have it recommended.
Keywords